TED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 1 7 2002

TECH CENTER 1600/2900

In re application of

E. Raspe et al.

Examiner: S. Chunduru

Serial No.: 09/646,924

Group Art Unit: 1656

Filed: September 25, 2000

USE OF ROR RECEPTORS FOR SCREENING SUBSTANCES USEFUL

FOR THE TREATMENT OF ATHEROSCLEROSIS

## **AMENDMENT**

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed to: Assistant Commissioner For Patents

Washington, D.C.

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

For:

In response to the Office Action of November 1, 2001, please amend the above-identified application as follows:

## **IN THE CLAIMS**:

Please amend claims 1, 3, 4, 7, 8, 16 and 22 as follows:

- 1. (Twice Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction comprising contacting said substance with a ROR receptor, or a response element thereof involved in the regulation of the apo C-III gene, and measuring the level of apo C-III gene expression.
- 3. (Twice Amended) A method of screening a substance for usefulness in the treatment of a lipid metabolism dysfunction, comprising contacting said substance with (a) a receptor of the ROR family involved in the regulation of the expression of the apo C-III gene, (b) a response element of the ROR receptor, or (c) a nuclear factor which functionally couples ROR to a RNA polymerase complex, and then measuring: